S. Gail Eckhardt, MD

home / authors / s-gail-eckhardt-md

Articles

Alternative Dosing Schedules for Irinotecan

Mace L. Rothenberg, MD;John G. Kuhn, PharmD;Larry J. Schaaf, PhD;Ronald L. Drengler, MD;S. Gail Eckhardt, MD;Miguel A. Villalona-calero, MD;Eric K. Rowinsky, MD;Daniel D. Von Hoff, MD;Langdon L. Miller, MD;Rrobert G. Petit, PhD;Lisa Hammond, MD

August 1st 1998

Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach

Irinotecan: A Review of the Initial Phase I Trials

S. Gail Eckhardt, MD

August 1st 1998

The unique mechanism of action of irinotecan (CPT-11 [Camptosar]), topoisomerase I inhibition, together with the results of preclinical studies, suggest that the drug’s antitumor and toxicologic effects may be schedule-dependent.

Irinotecan Plus Cisplatin in Patients With Advanced Non- Small-Cell Lung Cancer

Russell Devore Iii, MD;David Johnson, MD;Jeffrey Crawford, MD;Isaiah Dimery, MD;John Eckardt, MD;S. Gail Eckhardt, MD

August 1st 1998

During the 1980s, platinum-based regimens were yielding response rates typically less than 25%, median survival durations of about 25 weeks, and 1-year survival rates less than 25% in patients with advanced non-small-cell lung

New Anticancer Agents in Clinical Development

John Eckardt, MD;S. Gail Eckhardt, MD;Miguel A. Villalona-calero, MD;Ronald Drengler, MD

November 1st 1995

A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; the paclitaxel analog docetaxel; gemcitabine, an antimetabolite structurally related to cytarabine; and fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors.